tradingkey.logo
tradingkey.logo
Search

Xenon Pharmaceuticals Inc

XENE
Add to Watchlist
52.910USD
-0.290-0.55%
Close 06/18, 16:00ETQuotes delayed by 15 min
4.23BMarket Cap
LossP/E TTM

Earnings Forecast

Currency: USD Updated: 2026-06-18
Previous score
8.90
Change
0
The current earnings forecast score of Xenon Pharmaceuticals Inc is 8.90, ranking 39 out of 389 in the Biotechnology & Medical Research industry. The average price target is 55.00, with a high of 65.00 and a low of 44.00.

Analyst Rating

Based on 20 analysts
Buy
Current Rating
81.563
Target Price
+54.15%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Xenon Pharmaceuticals Inc
XENE
20
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Forecast
Actual

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

FAQs

What is Xenon Pharmaceuticals Inc's expected revenue for the next quarter?

Xenon Pharmaceuticals Inc's expected revenue is 1.36M.

What is Xenon Pharmaceuticals Inc's price target?

Analysts forecast that Xenon Pharmaceuticals Inc's price target is USD 55.00, with the highest forecast at USD 65.00 and the lowest forecast at USD 44.00.

How have Xenon Pharmaceuticals IncXENE's recent earnings per share performed?

The market expectation was USD -1.17, while Xenon Pharmaceuticals IncXENE's earnings per share (EPS) for the previous quarter was USD -1.31. EPS for the next quarter is expected at USD -1.12.

What is the analyst rating for Xenon Pharmaceuticals Inc?

Based on the ratings of Xenon Pharmaceuticals Inc's stock from 20 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
KeyAI